Sunstone Therapies has launched a new clinical trial evaluating group MDMA-assisted therapy for veterans living with PTSD. Supported by funding from the State of Maryland and Reason for Hope, the study will compare individual and group therapy models to assess safety, feasibility, and scalability. The research aims to expand access to evidence-based mental health care for veterans while generating critical insights into how psychedelic-assisted therapy may be delivered more effectively in the future.
As psychedelic-assisted therapies continue advancing through clinical research, understanding how they fit within existing mental health care systems is increasingly important. This article explores psychedelic-assisted therapy as a specialty intervention that can complement ongoing psychotherapy and psychiatric care through collaborative treatment models, referral pathways, and continuity of care. Discover how these treatments may help patients become more emotionally flexible and engaged when traditional approaches alone are not enough.
Researchers from Sunstone Therapies, Dana-Farber Cancer Institute, Harvard Medical School, and the University of Vermont have published new findings that deepen understanding of how psilocybin-assisted group therapy can help people with cancer and depression navigate profound existential challenges.
At Sunstone Therapies, we believe healing goes deeper than the surface. While traditional oncology focuses on physical treatments, many patients still struggle with the psychological and emotional challenges of cancer. Our mission is to address the whole patient, which is why we created the 2Dose Study. This clinical trial, led by Dr. Manish Agrawal, builds on our initial study where 80% of participants experienced a greater than 50% reduction in depressive symptoms. The 2Dose Study will explore whether psilocybin is more effective than an active placebo and if two doses are better than one. The trial is open to people with all stages of cancer, not just advanced disease.
A new paper published in Psychedelic Medicine introduces a novel model combining Meaning-Centered Psychotherapy (MCP) with psilocybin-assisted therapy (PAT) for patients with advanced cancer and depression. Developed from Sunstone Therapies’ investigator-initiated trial, the approach—called MCP-PSIL—aims to help patients reduce distress and find deeper meaning while navigating serious illness.
Co-founder and CEO, Dr. Manish Agrawal, recently shared his expertise and vision for the future of psychedelic-assisted therapy in oncology in a four-part interview series with Pharmacy Times’ Lead Editor, Alana Hippensteele.